Nevertheless, these observations indicate that mutant Kras plays a favorable role in FL118 anti-bladder cancer cell activity and could be used as a biomarker for bladder cancer patient selection for FL118 precision medicine. This evidence concerns the gene KRAS and urinary bladder carcinoma.